Mepi Mynol (Epinephrine Bitartrate, Mepivacaine Hydrochloride)

Epinephrine bitartrate stimulates α‑ and β‑adrenergic receptors, causing vasoconstriction at the injection site. This limits blood flow, reduces systemic absorption of mepivacaine, prolongs the duration of anesthesia, and helps control intra‑procedural bleeding.

The dose of Mepi Mynol is determined by the prescribing clinician based on the procedure, patient size, and clinical judgment. Only a qualified health professional should calculate and administer the appropriate volume for each individual case.

Safety data for Mepi Mynol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mepi Mynol combines a medium‑duration amide anesthetic (mepivacaine) with a vasoconstrictor (epinephrine), offering faster onset and longer duration than plain mepivacaine alone. Compared with lidocaine‑epinephrine mixtures, mepivacaine provides slightly less vasodilatory effect, which can be advantageous in patients sensitive to lidocaine.

Mepi Mynol should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and extreme temperatures to maintain potency and sterility.

Mepi Mynol is administered by infiltration injection directly into the tissue requiring anesthesia. The clinician injects the sterile solution using a suitable needle, ensuring proper aseptic technique and monitoring the patient for any immediate reactions.

Serious risks include anaphylactic reactions, severe cardiovascular events such as arrhythmias or hypertension, and systemic toxicity leading to seizures or prolonged numbness. Prompt recognition and management of these events are essential.

Patients with known hypersensitivity to mepivacaine, epinephrine, or any component of the formulation should avoid Mepi Mynol. It is also contraindicated in individuals with uncontrolled hypertension, certain cardiac arrhythmias, or those taking non‑selective beta‑blockers without medical supervision.